2023 Neuro-oncology Reading List

Reading List

Please click below to access the 2023 Neuro-oncology reading list.

2023 Neuro-oncology Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Integrate patient-centered outcomes into neuro-oncologic care management
  • Appropriately apply the results gathered from large patient populations in the management of primary brain tumor patients
  • Understand the prophylaxis and management of neurologic and treatment complications in primary brain tumors and brain metastases
  • Understand the role and clinical implications of targeted agents in neuro-oncology

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2023 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Neuro-oncology Certification Examination Committee Contributors

Christian Grommes, MD, Chair, Memorial Sloan Kettering Cancer Center
Disclosures: Received consultant fees from Ono, BTG, and Roche.

Andrea Wasilewski, MD, Vice Chair, Givens Brain Tumor Center
Disclosures: Nothing to disclose.


David M. Cachia, MD, UMass Memorial Medical Center
Disclosures: Received consulting fees from Red Hill BioPharma Ltd., Dedham Group, Guidepoint Global LLC; Speaker fee from Massachusetts Neurological Society. 


Yasmin Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Receive compensation as Editor-in-Chief of Pediatric Neurology; Nevus Outreach, Inc $10K annually.

Heather E. Leeper, MD, University of Chicago
Disclosures: Nothing to disclose.

Douglas E. Ney, MD, University of Colorado – Anschutz Medical Campus
Disclosures: Nothing to disclose.

Lauren Schaff, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Paid Ad hoc consultant to Guidepoint consulting company; BTG, plc - financial research support Merck - research support in the form of drug supply; Patent pending related to low-dose glucarpidase with methotrexate for treatment of CNS lymphoma.

Roy E. Strowd, III, MD, Wake Forest Baptist Health
Disclosures: Received medical consulting fees for Monteris Medical. Consulting lecturer for Kaplan and Lecturio and Springer Healthcare; Compensation for serving on the data safety monitoring board for study for schwannomatosis (NCT04163419); Editorial stipend from the AAN; Research support from Jazz pharmaceuticals.

Joon Uhm, MD, Mayo Clinic – Rochester 
Disclosures: Speaker fee received from Zai Labs for educational (Zoom) sessions to review current standard of care brain tumor therapies.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326